.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Accenture
US Department of Justice
Cantor Fitzgerald
Deloitte
Citi
Julphar
Queensland Health
Cipla

Generated: June 27, 2017

DrugPatentWatch Database Preview

Ondansetron hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ondansetron hydrochloride and what is the scope of ondansetron hydrochloride patent protection?

Ondansetron hydrochloride
is the generic ingredient in six branded drugs marketed by Aurobindo Pharma Ltd, Glaxosmithkline, Chartwell Molecules, Novartis Pharms Corp, Apotex, Taro, Qilu Pharm Co Ltd, West-ward Pharms Int, Pliva Hrvatska Doo, Taro Pharms Ireland, Lannett, Wockhardt, Sandoz, Emcure Pharms, Gland Pharma Ltd, Sandoz Inc, Mylan, Luitpold, Glenmark Generics, Aurobindo Pharma, Hospira, Silarx, Apotex Inc, Mylan Labs Ltd, Accord Hlthcare, Emcure Pharms Ltd, Hikma Intl Pharms, Sun Pharm Inds (in), Natco Pharma Ltd, Teva, Fresenius Kabi Usa, Ipca Labs Ltd, Sun Pharm Inds Ltd, Sagent Pharms, Hikma Farmaceutica, Amneal Pharms, Dr Reddys Labs Ltd, and Claris, and is included in seventy-one NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty-eight drug master file entries for ondansetron hydrochloride. Seventy suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: ondansetron hydrochloride

Tradenames:6
Patents:1
Applicants:38
NDAs:71
Drug Master File Entries: see list28
Suppliers / Packagers: see list70
Bulk Api Vendors: see list49
Clinical Trials: see list2,579
Patent Applications: see list1,329
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ondansetron hydrochloride at DailyMed

Pharmacology for Ingredient: ondansetron hydrochloride

Tentative approvals for ONDANSETRON HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
► Subscribe► SubscribeEQ 2MG BASE/MLINJECTABLE;INJECTION
► Subscribe► SubscribeEQ 2MG BASE/MLINJECTABLE;INJECTION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER
ondansetron hydrochloride
INJECTABLE;INJECTION020403-001Jan 31, 1995DISCNYesNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
INJECTABLE;INJECTION202599-001Dec 21, 2012APRXNoNo► Subscribe► Subscribe
Hospira
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER
ondansetron hydrochloride
INJECTABLE;INJECTION076978-001Feb 26, 2007DISCNNoNo► Subscribe► Subscribe
Hikma Farmaceutica
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
INJECTABLE;INJECTION076781-001Dec 26, 2006APRXNoNo► Subscribe► Subscribe
Mylan
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
TABLET;ORAL076930-002Jun 25, 2007ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ondansetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-003Aug 27, 19995,344,658*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-003Aug 27, 19995,578,628*PED► Subscribe
Novartis Pharms Corp
ZOFRAN PRESERVATIVE FREE
ondansetron hydrochloride
INJECTABLE;INJECTION020007-003Dec 10, 19934,753,789*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-001Dec 31, 19924,695,578*PED► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-002Dec 31, 19925,578,628*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Argus Health
Merck
Moodys
Deloitte
Baxter
McKinsey
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot